Findings

What do systematic reviews say?

9 questions · 9 findings · 2 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 66.7%High 0 · 0%

Topical clindamycin vs placebo

Adverse effects (non‐serious) · participants with hidradenitis suppurativa

Topical clindamycin showed no clear difference in adverse effects (non‐serious) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
RR 0.72 [0.14, 3.64]
1 study · 27 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

HRQOL RosaQoL · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Proportion of participants with adverse event · Participants with rosacea

Clindamycin phosphate 1.2% + tretinoin 0.025% gel probably leads to higher proportion of participants with adverse event compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
RR 2.45 [1.42, 4.23]
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Physician‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Assessment of erythema or telangiectasia · Participants with rosacea

Clindamycin phosphate 1.2% + tretinoin 0.025% gel showed no clear difference in assessment of erythema or telangiectasia compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
RR 1.71 [0.7, 4.18]
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Lesion count · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Time needed until improvement of the skin lesions · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Duration of remission ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found